Low dose estradiol valerate plus estriol can preserve bone loss in the forearm and attenuate climacteric symptoms in early postmenopausal women

Archives of Hellenic Medicine

Volumn 17, Issue 6, 2000, Pages 600-608

  Kamenov, Z ^a   Kolarov, G ^a   Orbetzova, M ^a   Aoki, N ^a   Imamura, M ^a   Higashino, H ^a   Protich, M ^a   Nalbanski, B ^a  

^a UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

Bone mineral density; Early menopause; Hamilton anxiety scale; Hormone replacement therapy; Kupperman menopausal index

Indexed keywords

ESTRADIOL VALERATE; ESTRIOL; LEVONORGESTREL;

ADULT; ARTICLE; BODY MASS; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; CLIMACTERIUM; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; MENSTRUATION; PHYSICAL ACTIVITY; POSTMENOPAUSE;

EID: 0034437247     PISSN: 11053992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices
2. Standardised assessment and recording of depressive symptoms
3. Estrogen improves psychological functioning in asymptomatic postmenopausal women
4. Neuroendocrinology of the climacteric period and HRT
5. Hormonal treatment of postmenopausal women
6. Hormone therapy to prevent disease and prolong life in postmenopausal women
7. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationship in early-postmenopausal women
8. Long term estrogen replacement therapy prevents bone loss and fractures
9. Estrogen treatment of patients with established postmenopausal osteoporosis
10. The diagnosis of osteoporosis
11. Bone composition in the distal forearm
12. Single X-ray absorptiometry of the forearm: Precision, correlation, and reference data
13. Diagnostic role of FSH measurements during the menopausal transition-an analysis of FSH, estradiol and inhibin
14. The endocrinology on the menopausal transition: A cross-sectional study of a population-based sample
15. The menopausal transition
16. Oestrogen and cyclical progestogen in postmenopausal hormone replacement therapy
17. Measuring the impact of menopausal symptoms on quality of life
18. Quality of life after the menopause: Influence of hormone replacement therapy
19. An alternative to hysterectomy? GnRH analogue combined with hormone replacement therapy
20. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee
21. Treatment of climacteric complaints with estriol
22. Effect of estriol on bone loss in postmenopausal Japanese women: A multicenter prospective open study
23. Estriol: Safety and efficacy
24. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: Long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding
25. Preventing postmenopausal osteoporosis with estrogen replacement therapy
26. Postmenopausal bone loss is prevented by treatment with low-dose estrogen with calcium
27. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation and hormone-replacement therapy
28. Clinical aspects of estrogens and osteoporosis
29. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: A population based 5-year randomized trial
30. Postmenopausal bone loss is prevented by treatment with low dose estrogen with calcium
31. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study
32. HRT and osteoporosis: Practical implications of new research findings
33. Add-back therapy in the treatment of endome-triosis: The European experience
34. Low and conventional dose transdermal estradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages
35. IS 1 mg of estradiol valerate or 0.625 mg of conjugated estrogens sufficient for all women to prevent menopausal bone loss?
36. Bone loss during estriol therapy in postmenopausal women
37. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women
38. Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women
39. Usefulness of estriol for the treatment of bone loss in postmenopausal women
40. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen, 1-alpha-hydroxyvitamin D3 and calcium lactate on vertebral bone loss in early menopausal women
41. Effect of estriol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women
42. The effects of menopause on longitudinal bone loss from the spine
43. Rates of bone loss in appendicular and axial skeletons of women
44. Effects of transdermal estradiol administration on bone mass and bone metabolism in early postmenopausal women
45. Estrogen therapy arrests bone loss in elderly women
46. Women with climacteric symptoms: A target group for prevention of rapid bone loss and osteoporosis
47. Bone turnover markers and bone density across the menopausal transition